Indegene acquires CultHealth

20 Oct 2022 , 06:08 AM

A full-service healthcare marketing organization for several life sciences firms, CultHealth, based in the US, has been bought by Indegene. Indegene is a technology company that helps life sciences companies commercialize their pharmaceuticals and medical devices.

The deal’s financial specifics were not disclosed by Bengaluru-based Indegene. The company’s US subsidiary ILSL Inc. helped it purchase CultHealth.

With the addition of platforms for patient involvement, the acquisition is anticipated to strengthen Indegene’s commercialization portfolio, which spans drug discovery and development to marketing and sales.

Indegene, the fastest-growing digital company providing services to the life sciences, had sales of $223 million in FY22.

The full-service healthcare marketing firm CultHealth is situated in the United States and has extensive knowledge of medical strategy, creative, and omnichannel planning services. It offers top-tier creatives for direct-to-consumer (DTC) advertising, including many accolade-winning digital TV/video ads.

CultHealth interacts with life sciences firms on a medical and academic level, bringing extensive knowledge of customer behavior and drug Mechanism of Action (MOA) to create superior advertising campaigns and creatives.

By 2025, it is anticipated that the world would spend $2.1 trillion on medical care. From 2022 to 2026, life sciences companies in the top 10 nations are anticipated to introduce 290-315 items, generating $196 billion in anticipated sales. But from 2004 to 2016, only 1 in 5 products introduced in the US generated $1 billion in sales, and 50% of all items introduced in the previous 15 years failed to reach the $250 million high.

Life sciences companies seek deep brand and marketing strategy expertise as they investigate contemporary, data-driven methods of ensuring launch success and creating a customized brand experience with omnichannel engagement journeys for patients and physicians in an environment of business and regulatory complexity.

For feedback and suggestions, write to us at [e-mail]